{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:07:33Z","timestamp":1790168853723,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A subset of eyes with neovascular AMD experience sub-optimal response to anti-VEGF therapy resulting in frequent injections. Faricimab has been used in this cohort due to reputed increased durability. Dosing strategies when switching vary, particularly regarding the need for a reloading phase. Our aim is to share our real-world experience of switching to faricimab with a clinician-directed dosing strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective analysis of eyes with neovascular AMD switched to faricimab from a previous anti-VEGF agent in Aneurin Bevan University Health Board, South Wales. Outcomes were evaluated at one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      173 eyes from 134 patients were analysed. Mean visual acuity remained stable at one year (\u20130.1 letters). There was a statistically significant reduction in central subfield thickness of 30.0\u2009\u03bcm (95% CI\u2009\u2212\u200941.1 to \u221218.9;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and an increase in injection interval of 2 weeks (95% CI 1.5 to 2.4;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Within these parameters, the \u2018Reloaded\u2019 subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102) showed no clear advantage over the \u2018Not reloaded\u2019 (interval matched\u2009\u00b1\u20092 weeks) subgroup (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200971). The \u2018Reloaded\u2019 subgroup had received fewer prior injections and had shorter baseline injection intervals before switching.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching to faricimab was associated with stable vision, reduced macular oedema and increased injection intervals at one year. A clinician-directed dosing strategy at switching yielded comparable outcomes between subgroups, suggesting a reloading phase may not be required for all eyes. This has potential benefits for reducing demand on service capacity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04686-9","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:17:07Z","timestamp":1783084627000},"page":"2199-2205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real world experience with faricimab in switched neovascular AMD and evaluation of reloading versus interval matching regimes"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5818-9756","authenticated-orcid":false,"given":"Ffion E.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhuparna","family":"Mitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"4686_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2023.26074","volume":"331","author":"M Fleckenstein","year":"2024","unstructured":"Fleckenstein M, Schmitz-Valckenberg S, Chakravarthy U. Age-related macular degeneration: a review. JAMA. 2024;331:147\u201357.","journal-title":"JAMA"},{"key":"4686_CR2","first-page":"364","volume":"8","author":"N Boopathiraj","year":"2024","unstructured":"Boopathiraj N, Wagner IV, Dorairaj SK, Miller DD, Stewart MW. Recent updates on the diagnosis and management of age-related macular degeneration. Mayo Clin Proc: Innov, Qual Outcomes. 2024;8:364\u201374.","journal-title":"Mayo Clin Proc: Innov, Qual Outcomes"},{"key":"4686_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3390\/life14020193","volume":"14","author":"B Ng","year":"2024","unstructured":"Ng B, Kolli H, Ajith Kumar N, Azzopardi M, Logeswaran A, Buensalido J, et al. Real-world data on faricimab switching in treatment-refractory neovascular age-related macular degeneration. Life. 2024;14:193.","journal-title":"Life"},{"key":"4686_CR4","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1007\/s40123-024-00999-8","volume":"13","author":"T Li","year":"2024","unstructured":"Li T, Berdunov V, Hamilton R, Rojas YG, B\u00fchrer C, Cox O, et al. Economic assessment in resource-constrained systems: individual-level simulation model in wet age-related macular degeneration and diabetic macular oedema. Ophthalmol Ther. 2024;13:2577\u201397.","journal-title":"Ophthalmol Ther"},{"key":"4686_CR5","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20146 month results. Eye. 2023;37:3574\u201381.","journal-title":"Eye"},{"key":"4686_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729\u201340.","journal-title":"Lancet"},{"key":"4686_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00566-0","volume":"10","author":"N Nasimi","year":"2024","unstructured":"Nasimi N, Nasimi S, Grauslund J, Vergmann AS, Subhi Y. Real-world efficacy of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review. Int J Retin Vitreous. 2024;10:48.","journal-title":"Int J Retin Vitreous"},{"key":"4686_CR8","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","volume":"13","author":"G Cancian","year":"2024","unstructured":"Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, et al. One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration. Ophthalmol Ther. 2024;13:2985\u201397.","journal-title":"Ophthalmol Ther"},{"key":"4686_CR9","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","volume":"38","author":"C Goodchild","year":"2024","unstructured":"Goodchild C, Bailey C, Soto Hernaez J, Ahmed E, Salvatore S. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye. 2024;38:3059\u201364.","journal-title":"Eye"},{"key":"4686_CR10","doi-asserted-by":"crossref","unstructured":"Cheng AM, Joshi S, Banoub RG, Saddemi J, Chalam KV. Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration. Cureus. 2023;15:e40100.","DOI":"10.7759\/cureus.40100"},{"key":"4686_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","volume":"262","author":"G Grimaldi","year":"2024","unstructured":"Grimaldi G, Cancian G, Rizzato A, Casanova A, Perruchoud-Ader K, Clerici M, et al. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study. Graefes Arch Clin Exp Ophthalmol. 2024;262:1151\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"4686_CR12","unstructured":"Roche Products Limited. Vabysmo 120 mg\/mL solution for injection: Electronic Medicines Compendium (EMC); [Available from: https:\/\/www.medicines.org.uk\/emc\/product\/13741\/smpc#gref.(2025)"},{"key":"4686_CR13","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","volume":"38","author":"GA Borchert","year":"2024","unstructured":"Borchert GA, Kiire CA, Stone NM, Akil H, Gkika T, Fischer MD, et al. Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema. Eye. 2024;38:3569\u201377.","journal-title":"Eye"},{"key":"4686_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","volume":"9","author":"SY Sim","year":"2025","unstructured":"Sim SY, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel PJ, et al. Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab. Ophthalmol Retin. 2025;9:22\u201330.","journal-title":"Ophthalmol Retin"},{"key":"4686_CR15","doi-asserted-by":"crossref","unstructured":"Hao Q, Bailey S. CADTH Health Technology Review. Anti\u2013Vascular Endothelial Growth Factor Drugs for Age-Related Macular Degeneration. CADTH Health Technology Review. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2023.","DOI":"10.51731\/cjht.2023.771"},{"key":"4686_CR16","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s10384-023-01024-4","volume":"67","author":"T Hikichi","year":"2023","unstructured":"Hikichi T. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration. Jpn J Ophthalmol. 2023;67:652\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"4686_CR17","unstructured":"Real-World Vabysmo Symposium - South West & Wales. 15th and 16th March, Bristol. (2024)."},{"key":"4686_CR18","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/09273948.2023.2293925","volume":"32","author":"F Palmieri","year":"2024","unstructured":"Palmieri F, Younis S, Bedan Hamoud A, Fabozzi L. Uveitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflamm. 2024;32:1873\u20137.","journal-title":"Ocul Immunol Inflamm"},{"key":"4686_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A, Chen S-J, Chen Y, Guymer R, et al. TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2. Ophthalmology. 2024;131:914\u201326.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04686-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04686-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:45:18Z","timestamp":1790167518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04686-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":19,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4686"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04686-9","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}